Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.73 USD

51.73
1,388,647

+0.47 (0.92%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $51.74 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Mitchell Moore headshot

What to Expect from Sanofi's (SNY) Q2 Earnings

by Mitchell Moore

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

Kinjel Shah headshot

Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright

by Kinjel Shah

The Zacks Large Cap Pharmaceuticals industry underperforms the sector and S&P 500. However it ranks in the top 19% of more than 250 Zacks industries.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for July 18th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs

by Zacks Equity Research

Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.

Merck's Antibiotic Recarbrio Gets FDA Nod for Infections

by Zacks Equity Research

The FDA approves Merck's (MRK) anti-bacterial injection, MK-7655A, to be marketed as Recarbrio.

AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes

by Zacks Equity Research

AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.

Aimmune Down on Negative ICER Review on Allergy Candidate

by Zacks Equity Research

Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.

SNY or PFE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SNY vs. PFE: Which Stock Is the Better Value Option?

Are Investors Undervaluing Sanofi (SNY) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kinjel Shah headshot

Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY

by Kinjel Shah

Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.

FDA Accepts Sanofi's BLA for Myeloma Candidate to Review

by Zacks Equity Research

The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.

Court Ruling Topples Trump Order, No Price Display in TV Ads

by Zacks Equity Research

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

Kinjel Shah headshot

Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs

by Kinjel Shah

Pfizer (PFE) provides several regulatory/pipeline updates. CHMP gives nod to several drugs.

Glaxo's Dovato Wins EU Nod, RA Candidate Enters Phase III

by Zacks Equity Research

Glaxo (GSK) gets an EU approval for Dovato, its single-tablet two-drug HIV regimen. It commences phase III studies on its anti GM-CSF antibody, otilimab, for patients with rheumatoid arthritis.

Roche's Flu Medicine Xofluza Meets Goal in Study on Kids

by Zacks Equity Research

Roche's (RHHBY) new flu medicine, Xofluza is well tolerated in a study in children aged between one to 12 years. It is also comparable to Roche's older flu medicine, Tamiflu,

Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance

by Zacks Equity Research

Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019.

Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis

by Zacks Equity Research

Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.

Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer

by Zacks Equity Research

Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.

Regeneron/Sanofi's Dupixent Gets Positive CHMP Recommendation

by Zacks Equity Research

Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.

Novavax (NVAX) Seeks Accelerated Approval Pathway for NanoFlu

by Zacks Equity Research

Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.

FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review

by Zacks Equity Research

The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.

Regeneron & Sanofi Get FDA Nod for Dupixent Label Expansion

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.

Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

by Zacks Equity Research

Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.

Kinjel Shah headshot

Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod

by Kinjel Shah

Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.

The Zacks Analyst Blog Highlights: Alphabet, Amazon, Apple, Sanofi and Walgreens

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alphabet, Amazon, Apple, Sanofi and Walgreens